000300631 001__ 300631
000300631 005__ 20250427020248.0
000300631 0247_ $$2doi$$a10.1002/cam4.70908
000300631 0247_ $$2pmid$$apmid:40259875
000300631 0247_ $$2altmetric$$aaltmetric:176359291
000300631 037__ $$aDKFZ-2025-00845
000300631 041__ $$aEnglish
000300631 082__ $$a610
000300631 1001_ $$0P:(DE-He78)80f716879524b90b0ca1050b30f8279e$$aOnyedibe, Maria Chidi Christiana$$b0$$eFirst author
000300631 245__ $$aSubjective and Objective Cancer-Related Cognitive Impairments Among Systemic and Radiation Therapy-Naïve Female Cancer Patients.
000300631 260__ $$aHoboken, NJ$$bWiley$$c2025
000300631 3367_ $$2DRIVER$$aarticle
000300631 3367_ $$2DataCite$$aOutput Types/Journal article
000300631 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1745414903_30949
000300631 3367_ $$2BibTeX$$aARTICLE
000300631 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300631 3367_ $$00$$2EndNote$$aJournal Article
000300631 500__ $$a#EA:C110#LA:C110#
000300631 520__ $$aCancer-related cognitive impairment (CRCI) is a frequent and burdensome problem that is still insufficiently understood and managed. We investigated subjective and objective measures of CRCI, as recommended by the International Cancer and Cognition Task Force (ICCTF) in cancer patients prior to systemic or radiation therapy with respect to potential influencing or associated psychosocial, demographic, or lifestyle factors.Female patients with breast or gynecological tumors (n = 239, mean age = 55.5, SD = 11.6) prior to any systemic or radiation therapy completed validated subjective (FACT-Cog: perceived cognitive impairment [PCI], perceived cognitive ability [PCA], impact on quality of life [IQoL]) and objective measures of CRCI (Trail Making Test [TMT-A and -B], Controlled Oral Word Association Test [COWA], and Hopkins Verbal Learning Test-Revised [HVLT-R]). Association with cross-sectionally assessed age, body mass index, education, smoking, alcohol intake, sleep problems, social support, anxiety, and pain was investigated using multiple linear regression models.A quarter (25.1%) of patients showed indication for CRCI based on the PCI score. Subjective and objective CRCI measures showed no or only weak correlations, also when adjusting for age and education (partial Spearman correlations with each other, all |r| ≤ 0.21). Anxiety, sleep problems, and pain were significantly associated with low subjective cognitive function (PCI, PCA, and IQoL). Poor objective cognitive values (TMT, COWA, and HVLT-R) were mainly determined by higher age and lower education.Cancer-related cognitive impairment is not solely (chemo-)therapy-induced but may be triggered or influenced by anxiety, sleep problems, and pain. Addressing these issues early in the treatment phase could potentially alleviate perceived CRCI. The ICCTF-recommended neuropsychological tests do not adequately capture this CRCI prior to systemic or radiation therapy, but could serve as complementary tools to monitor cognitive changes over time, independent of psychosocial influences.
000300631 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000300631 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000300631 650_7 $$2Other$$aanxiety
000300631 650_7 $$2Other$$abreast cancer
000300631 650_7 $$2Other$$acancer‐related cognitive impairment
000300631 650_7 $$2Other$$aneuropsychological tests
000300631 650_7 $$2Other$$asleep problem
000300631 650_2 $$2MeSH$$aHumans
000300631 650_2 $$2MeSH$$aFemale
000300631 650_2 $$2MeSH$$aMiddle Aged
000300631 650_2 $$2MeSH$$aQuality of Life
000300631 650_2 $$2MeSH$$aAged
000300631 650_2 $$2MeSH$$aCognitive Dysfunction: etiology
000300631 650_2 $$2MeSH$$aCognitive Dysfunction: epidemiology
000300631 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000300631 650_2 $$2MeSH$$aCognitive Dysfunction: psychology
000300631 650_2 $$2MeSH$$aAdult
000300631 650_2 $$2MeSH$$aBreast Neoplasms: complications
000300631 650_2 $$2MeSH$$aBreast Neoplasms: psychology
000300631 650_2 $$2MeSH$$aBreast Neoplasms: therapy
000300631 650_2 $$2MeSH$$aCross-Sectional Studies
000300631 650_2 $$2MeSH$$aGenital Neoplasms, Female: complications
000300631 650_2 $$2MeSH$$aGenital Neoplasms, Female: psychology
000300631 650_2 $$2MeSH$$aGenital Neoplasms, Female: therapy
000300631 650_2 $$2MeSH$$aNeuropsychological Tests
000300631 7001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b1$$eFirst author$$udkfz
000300631 7001_ $$0P:(DE-He78)99e08c106da1c0aae8cb9f2dff77165f$$aBizer, Pauline$$b2
000300631 7001_ $$aZimmer, Philipp$$b3
000300631 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b4$$eLast author$$udkfz
000300631 773__ $$0PERI:(DE-600)2659751-2$$a10.1002/cam4.70908$$gVol. 14, no. 8, p. e70908$$n8$$pe70908$$tCancer medicine$$v14$$x2045-7634$$y2025
000300631 909CO $$ooai:inrepo02.dkfz.de:300631$$pVDB
000300631 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)80f716879524b90b0ca1050b30f8279e$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000300631 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000300631 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)99e08c106da1c0aae8cb9f2dff77165f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000300631 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000300631 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000300631 9141_ $$y2025
000300631 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-07$$wger
000300631 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER MED-US : 2022$$d2025-01-07
000300631 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000300631 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000300631 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:04:21Z
000300631 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:04:21Z
000300631 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-08T17:04:21Z
000300631 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-08-08T17:04:21Z
000300631 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000300631 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000300631 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000300631 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
000300631 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000300631 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
000300631 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
000300631 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000300631 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000300631 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000300631 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-07
000300631 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-07
000300631 9202_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000300631 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000300631 9200_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000300631 980__ $$ajournal
000300631 980__ $$aVDB
000300631 980__ $$aI:(DE-He78)C110-20160331
000300631 980__ $$aUNRESTRICTED